Thermo Fisher’s Q3 Revenues Rise 7 Percent
 
Thermo Fisher Scientific last week said that its third-quarter revenues rose 7 percent to $2.4 billion on a pro forma basis.
 
The company also hinted in a statement that the “highly fragmented” market in which it plays “presents opportunities” to make additional acquisitions.
 
Thermo Fisher stressed that last year's results reflect Thermo Electron's operations before its merger with Fisher Scientific last November.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.